stoxline Quote Chart Rank Option Currency Glossary
BiomX Inc. (PHGE)
0.3601  0.02 (5.91%)    05-28 15:59
Open: 0.36
High: 0.389
Volume: 213,847
Pre. Close: 0.34
Low: 0.3311
Market Cap: 25(M)
Technical analysis
2024-05-28 4:24:53 PM
Short term     
Mid term     
Targets 6-month :  0.49 1-year :  0.58
Resists First :  0.42 Second :  0.49
Pivot price 0.35
Supports First :  0.3 Second :  0.24
MAs MA(5) :  0.35 MA(20) :  0.37
MA(100) :  0.3 MA(250) :  0.33
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  36.2 D(3) :  35.7
RSI RSI(14): 51.3
52-week High :  0.85 Low :  0.18
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PHGE ] has closed below upper band by 39.0%. Bollinger Bands are 58.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.39 - 0.39 0.39 - 0.39
Low: 0.33 - 0.33 0.33 - 0.33
Close: 0.36 - 0.36 0.36 - 0.36
Company Description

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Headline News

Sat, 25 May 2024
HC Wainwright Equities Analysts Decrease Earnings Estimates for BiomX Inc. (NYSEMKT:PHGE) - Defense World

Tue, 21 May 2024
Earnings call: BiomX reports Q1 2024 results, optimistic on phage therapies -

Tue, 21 May 2024
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates - GlobeNewswire

Fri, 05 Apr 2024
Biomx Inc. at a Crossroads: Shareholder Approval Required for Convertible Securities Amid Liquidity Concerns ... - TipRanks

Thu, 04 Apr 2024
BiomX Inc. (AMEX:PHGE) Q4 2023 Earnings Call Transcript - Yahoo Finance

Mon, 11 Mar 2024
BiomX, APT merger to advance CF treatment into Phase 2 trial - Cystic Fibrosis News Today

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 47 (M)
Shares Float 32 (M)
Held by Insiders 26.4 (%)
Held by Institutions 16.2 (%)
Shares Short 98 (K)
Shares Short P.Month 8 (K)
Stock Financials
EPS -0.63
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.18
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -37.8 %
Return on Equity (ttm) -153.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.56
Qtrly Earnings Growth 0 %
Operating Cash Flow -22 (M)
Levered Free Cash Flow -13 (M)
Stock Valuations
PE Ratio -0.58
PEG Ratio 0
Price to Book value 2
Price to Sales 0
Price to Cash Flow -0.77
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android